Adjuvant radiotherapy after surgery for high-risk adrenal cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether giving radiation therapy after surgery for adrenocortical carcinoma (a rare cancer of the adrenal gland) can improve outcomes compared to just watching and waiting. It is for patients who have certain high-risk features that make the cancer more likely to come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had surgery to remove your adrenal cancer and the pathology report confirms it is adrenocortical carcinoma.
- Your cancer must be localized (not spread to distant parts of the body) but may have high-risk features like a high Ki-67 score, positive margins, or stage 3 disease.
- You need to be in generally good health (able to care for yourself and expected to live at least 6 months).
- An imaging scan after surgery must show no remaining or spread of the cancer.
- You must not have had prior radiation therapy to the abdomen or pelvis, and no other active cancer (except certain minor skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.